Azurity Patent-Cliff Exposure & CMS Drug Spending Portfolio

Azurity (US): 41 reconciled FDA prescription therapies (42.0% 2025 to 2030 cliff risk), $229.4M 2024 CMS Part D & Medicaid spend, and 61 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies41
2025 to 2030 Patent-Cliff Revenue Exposure42.0%
Primary Portfolio LOE Date2026-01-01
2024 CMS Total Public Spend$229.4M
2024 Medicare Part D Spend$106.3M
2024 Medicaid Spend$123.1M
California HCAI SB 17 Filings61 WAC filings (max 26.4% 2-yr change)